Eylea (aflibercept intravitreal) - Regeneron
Opuviz (aflibercept-yszy) - AffaMed Therap, Biogen, Samsung, Harrow Health, Samil Pharma, Teva
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema (clinicaltrials.gov) - Oct 15, 2026 - P2 | N=33 | Completed | Sponsor: Samsung Bioepis Co., Ltd. | Active, not recruiting ➔ Completed 
Trial completion • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration
http://clinicaltrials.gov/ct2/show/NCT07844343
 
Oct 15, 2026
 
Prev Next